@article{cd4234660fa94a9ca4f923ec43a31b4c,
title = "Patient Reported Outcomes (PROs) with Poly(ADP-ribose) Polymerase Inhibitors (PARPi) versus Chemotherapy (CTX) in Patients (pts) with Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- advanced Breast Cancer (ABC): Results from a Multi-country Real-world (RW) Study",
abstract = " A. Niyazov; K. Lewis; J. Pike; A. Rider; B. Arondekar; M. Lux ",
author = "Reshma Mahtani",
note = "Abstract. Background: In ABC, where treatment is palliative, an important goal is the maintenance or improvement of quality of life (QoL). In the past 3 years, PARPi have demonstrated improved progression-free survival and favorable PROs compared with CTX in randomized clinical trials (RCTs) in pts with ABC and a gBRCA1/2mut.",
year = "2021",
month = feb,
day = "15",
language = "American English",
volume = "81",
journal = "Cancer Research / San Antonio Breast Cancer Symposium",
}